基线肾病范围蛋白尿是否决定膜性狼疮肾炎患者的长期结局:膜性狼疮肾炎中的肾病范围蛋白尿
该回顾性研究纳入88例经活检证实的膜性狼疮肾炎患者,按基线蛋白尿分为亚肾病组(<3.5 g/天,49例)和肾病组(≥3.5 g/天,39例)。两组肾脏疾病特征及长期不良复合结局和狼疮肾炎复发率均无显著差异,作者认为这挑战了当前实践,提示需要更个体化的免疫抑制治疗。
要点
- 88例膜性狼疮肾炎患者中,亚肾病组49例(55.7%),肾病组39例(44.3%)。
- 不良复合结局发生率亚肾病组40.8% vs 肾病组46.2%,无显著差异(p=0.78)。
- 狼疮肾炎复发率亚肾病组38.8% vs 肾病组41.0%,无显著差异(p=1.00)。
核心结论
- 膜性狼疮肾炎患者中,基线肾病范围与亚肾病范围蛋白尿者的肾脏疾病特征及长期结局无显著差异。
- 作者认为这些发现挑战了当前实践,提示需要更个体化的免疫抑制治疗。
研究设计与样本
- 回顾性研究,纳入经活检证实的膜性狼疮肾炎患者88例。
- 按基线蛋白尿水平分为亚肾病组(<3.5 g/天,49例)和肾病组(≥3.5 g/天,39例)。
- 采用Kaplan-Meier曲线评估时间-事件结局,Cox回归评估关联。
主要发现
- 亚肾病组基线蛋白尿中位数1.5 g/天,肾病组中位数4.7 g/天。
- 基线时亚肾病组狼疮肾炎发病时间更长、高脂血症更少、血清白蛋白更高、弥漫性足细胞足突消失更少、环磷酰胺治疗更少。
- 两组在肾功能、尿沉渣异常或组织病理学方面无显著差异。
- 38例(43.2%)发生不良复合结局(终末期肾病、eGFR持续下降≥30%或死亡),亚肾病组40.8% vs 肾病组46.2%,p=0.78。
- 35例(39.8%)发生狼疮肾炎复发,亚肾病组38.8% vs 肾病组41.0%,p=1.00。
临床怎么用
- 作者认为当前基于蛋白尿严重程度的管理策略受到挑战,提示需要更个体化的免疫抑制治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Management strategies for membranous lupus nephritis (MLN) are generally based on the severity of proteinuria. However, long-term outcomes comparing subnephrotic and nephrotic range proteinuria remain understudied. We explored whether baseline proteinuria level, subnephrotic or nephrotic, impacts long-term outcomes. METHODS: We conducted a retrospective study identifying patients with biopsy-proven MLN. Patients were categorized based on baseline proteinuria: subnephrotic (<3.5 g/day) or nephrotic (≥3.5 g/day). Long-term outcomes, including an adverse composite outcome (end-stage kidney disease, sustained ≥30 % decline in eGFR, or death) and LN flares, were analyzed. Time-to-event outcomes were assessed using Kaplan-Meier curves, and associations were evaluated using Cox regression. RESULTS: 88 patients were included, with 49 (55.7 %) in the subnephrotic group (median 1.5 g/day) and 39 (44.3 %) in the nephrotic group (median 4.7 g/day). At baseline, the subnephrotic group had a longer time to LN onset, less frequent hyperlipidemia, higher serum albumin, less diffuse podocyte effacement, and less frequent cyclophosphamide treatment. No significant differences were noted in kidney function, urine sediment abnormalities, or histopathology. 38 patients (43.2 %) experienced the adverse composite outcome, with no difference between groups (40.8 % in the subnephrotic group vs. 46.2 % in the nephrotic group, p = 0.78]. Flares occurred in 35 patients (39.8 %), with no difference between groups (38.8 % in the subnephrotic group vs. 41.0 % in the nephrotic group, p = 1.00). CONCLUSIONS: No significant differences in renal disease characteristics or long-term outcomes were found between MLN patients with nephrotic and subnephrotic baseline proteinuria. These findings challenge current practices, suggesting a need for more individualized immunosuppressive treatment in MLN.
引用
- Kharouf F, Mehta P, Carrizo Abarza V, et al. Does baseline nephrotic range proteinuria determine the long-term outcomes of membranous lupus nephritis patients?: Nephrotic Range Proteinuria in Membranous Lupus Nephritis. Semin Arthritis Rheum. 2025. PMID: 40403525. doi:10.1016/j.semarthrit.2025.152756
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。